A consortium that includes medical diagnostics company Omega is working with the Medicines and Healthcare products Regulatory Agency (MHRA) to enable approval for its Covid-19 lateral flow antibody test.
The Alva-based company is part of the consortium led by AIM-listed Abingdon Health developing the AbC-19 Rapid Test.
Abingdon, which is York-based, said that while the UK's Department of Health and Social Care has first refusal of supplies of the test through a contract that runs to 14 February, it is also working on potential international distribution.
The UK Rapid Test Consortium liaising with customers and regulatory authorities across a total of 27 international territories, to allow future use of the product outside of the UK.
Omega Diagnostics CEO Colin King said: “We welcome the update from Abingdon Health this morning and we look forward to being able to update investors on this approval process for self-test use in due course.
“We remain confident that the AbC-19 Rapid Test has a potential global application and we are delighted that the UK-RTC maintains constructive dialogue with interested customers and regulatory authorities across the world.”
Abingdon Health raised £22m with a listing on the Alternative Investment Market on 15 December.
